Psychiatric Diagnoses and Medications in Wolfram Syndrome
- PMID: 36687263
- PMCID: PMC9828213
- DOI: 10.2478/sjcapp-2022-0017
Psychiatric Diagnoses and Medications in Wolfram Syndrome
Abstract
Background: Wolfram Syndrome is a rare genetic disorder usually resulting from pathogenic variation in the WFS1 gene, which leads to an exaggerated endoplasmic reticulum (ER) stress response. The disorder is typically characterized by diabetes insipidus, diabetes mellitus, optic nerve atrophy, hearing loss, and neurodegenerative features. Existing literature suggests it may also have psychiatric manifestations.
Objective: To examine lifetime psychiatric diagnoses and medication history in Wolfram Syndrome.
Method: Child, adolescent, and young adult Wolfram Syndrome participants (n=39) were assessed by a child & adolescent psychiatrist to determine best estimate DSM-5 lifetime psychiatric diagnoses as well as psychoactive medication history. In addition, the Child & Adolescent Symptom Inventory-5 (CASI-5) Parent Checklist was used to determine likely psychiatric diagnoses based on symptom counts in Wolfram Syndrome patients (n=33), type 1 diabetes (n=15), and healthy comparison (n=18) groups.
Results: Study participants with Wolfram Syndrome had high lifetime rates of anxiety disorders (77%). Also, 31% had an obsessive-compulsive spectrum disorder, 33% had a mood disorder, 31% had a neurodevelopmental or disruptive behavior disorder, and 31% had a sleep-wake disorder. More than half of Wolfram Syndrome participants had taken at least one psychoactive medication, and one third had taken at least one selective serotonin reuptake inhibitor (SSRI). Some individuals reported poor response to sertraline but better response after switching to another SSRI (fluoxetine or citalopram). In general, people with Wolfram Syndrome often reported benefit from psychotherapy and/or commonly used psychoactive medications appropriate for their psychiatric diagnoses.
Conclusions: Wolfram Syndrome may be associated with elevated risk for anxiety and obsessive-compulsive spectrum disorders, which seem generally responsive to usual treatments for these disorders.
Keywords: Anxiety; ER stress; Obsessive Compulsive Disorder; Psychiatry; Wolfram Syndrome; medication.
© 2022 Angela M. Reiersen, Jacob S. Noel, Tasha Doty, Richa A. Sinkre, Anagha Narayanan, Tamara Hershey, published by Sciendo.
Figures

Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
WFS1 Spectrum Disorder.2009 Feb 24 [updated 2022 Dec 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2009 Feb 24 [updated 2022 Dec 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301750 Free Books & Documents. Review.
-
Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003018. doi: 10.1002/14651858.CD003018.pub3. Cochrane Database Syst Rev. 2011. PMID: 22161373 Free PMC article.
-
Pharmacotherapy for anxiety and comorbid alcohol use disorders.Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2. Cochrane Database Syst Rev. 2015. PMID: 25601826 Free PMC article.
Cited by
-
Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models.medRxiv [Preprint]. 2024 Sep 11:2024.09.10.24313426. doi: 10.1101/2024.09.10.24313426. medRxiv. 2024. Update in: PLoS One. 2025 May 9;20(5):e0321598. doi: 10.1371/journal.pone.0321598. PMID: 39314971 Free PMC article. Updated. Preprint.
-
Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models.PLoS One. 2025 May 9;20(5):e0321598. doi: 10.1371/journal.pone.0321598. eCollection 2025. PLoS One. 2025. PMID: 40344084 Free PMC article.
-
Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease.Genes (Basel). 2024 Jul 25;15(8):984. doi: 10.3390/genes15080984. Genes (Basel). 2024. PMID: 39202345 Free PMC article. Review.
-
The LEADING Guideline: Reporting Standards for Expert Panel, Best-Estimate Diagnosis, and Longitudinal Expert All Data (LEAD) Studies.medRxiv [Preprint]. 2024 Sep 4:2024.03.19.24304526. doi: 10.1101/2024.03.19.24304526. medRxiv. 2024. Update in: Compr Psychiatry. 2025 Aug;141:152603. doi: 10.1016/j.comppsych.2025.152603. PMID: 38699296 Free PMC article. Updated. Preprint.
References
-
- Minton JA, Rainbow LA, Ricketts C, Barrett TG. Wolfram syndrome. Rev Endocr Metab Disord. 2003;4(1):53–9. - PubMed
-
- Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83(5):921–929. - PubMed
-
- Yamada T, Ishihara H, Tamura A, Takahashi R, Yamaguchi S, Takei D, Tokita A, Satake C, Tashiro F, Katagiri H, Aburatani H, Miyazaki J, Oka Y. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet. 2006;15(10):1600–9. - PubMed
-
- Altpere A, Raud S, Sütt S, Reimets R, Visnapuu T, Toots M, Vasar E. Mild stress induces brain region-specific alterations of selective ER stress markers’ mRNA expression in Wfs1-deficient mice. Behav Brain Res. 2018;352:94–98. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources